Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2013. The report details a specific share repurchase transaction executed on October 4, 2013, in accordance with shareholder authority granted at the Annual General Meeting on May 1, 2013.
Key Financial Metrics
The filing does not provide comprehensive financial statements such as revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on capital structure changes related to share buybacks.
- Shares Purchased: 1,435,000 Ordinary Shares of 25 pence each.
- Price Range: Highest price paid was 1,573.50 pence per share; lowest price paid was 1,555.50 pence per share.
- Treasury Holdings (Settled): 484,364,412 shares (9.03% of total issued share capital).
- Treasury Holdings (Including Unsettled): 490,129,412 shares (10.04% of current total voting rights).
- Shares in Issue (Excluding Treasury): 4,881,498,670 shares.
Material Changes
The primary material change reported is the reduction of outstanding shares through the purchase of 1,435,000 shares for Treasury. This transaction increased the proportion of shares held in Treasury to 9.03% of issued capital and 10.04% of total voting rights when including unsettled transactions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It is a compliance disclosure confirming adherence to the Financial Conduct Authority's Disclosure and Transparency Rules regarding share ownership notifications.
Investor Verification Checklist
- Verify the total number of shares held in Treasury (484,364,412 settled) against the company's latest capitalization table.
- Confirm the calculation of voting rights, noting that 10.04% of voting rights are currently held in Treasury including unsettled trades.
- Check the denominator for shareholder notification thresholds, which is 4,881,498,670 shares (excluding Treasury).
- Review the price paid per share (1,555.50 to 1,573.50 pence) to assess the cost of capital reduction relative to market prices on October 4, 2013.